Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon May 27, 2022 1:26pm
121 Views
Post# 34712685

RE:RE:RE:Deleting comments

RE:RE:RE:Deleting comments
StockingUp21 wrote:

You get a point for every post, this does not mean respect.

Put me down but ignore years of pumping and being wrong. His old account is banned before and has other usernames. Never will say how many shares it owns.  This is proven. 

 




You are so petty Stockings.

Ask "Woundedknee" if he hated my name - changed it for him and I understood why he didn't like it.  The entire story is here at SH if you've been paying attention.

How many shares do you want me to tell you I have? 
It's certainly not about the number - because - you want me to show you proof.
Sorry - I'm not in that game !!!

I'll tell you my average price is around $1.40 and you'll learn more as time goes on.

As for being wrong ... what specificially have I been wrong about in your short existance?

Was I wrong when I said China and LATAM were potentials for partnering?
Was I wrong when I said due to IFRS 5 rules, we likely see a sale of CITA before Sept 2022?
Was I wrong to think chronic pain is far from over and everything is still on the table?
Wrong that a new patent for chronic is in the works and related to "method?"

I'm going to cry like a baby or I'm going to jump for joy - nothing wrong about that statement !!!

Start moving your hips Stockings - or get off the dance floor.  I've got my goldfish platform shoes on and I'm going to use the entire floor.  You may not want to see me out there but I'm not going anywhere.

Tonight we dance !!!!
You - get educated in ATE.

: )
<< Previous
Bullboard Posts
Next >>